MBX Biosciences (MBX) shares were about 1.0% lower in Thursday trading following its Q2 results.
Earlier, the clinical-stage biopharmaceutical company reported a Q2 net loss of $0.78 per share, compared with a loss of $0.58 a year ago.
Looking ahead, the firm said its cash and investments are expected to support operations into 2029.
Price: $66.78, Change: $-0.70, Percent Change: -1.04%
Cirrus Logic (CRUS) reported fiscal Q1 adjusted earnings late Wednesday of $1.84 per diluted share, up from $1.51 a year earlier.Analysts polled by FactSet expected $1.81.Revenue in the three months ended June 27 rose to $459.7 million from $407.3 million a year ago.Four analysts expected $460.3 million.The company expects fiscal Q2 revenue of $510 million to $570 million. Analysts project $570.1 million.Cirrus Logic shares fell 3.4% in after-hours trading.
Tenaris (TS) reported Q2 earnings late Wednesday of $0.95 per American depository share, down from $0.99 a year earlier.Four analysts polled by FactSet expected $0.83.Revenue in the three months ended June 30 fell to $2.97 billion from $3.09 billion a year earlier.Analysts expected $2.93 billion.Tenaris shares fell 5.5% in after-hours trading.
Block (XYZ) reported Q2 adjusted earnings late Wednesday of $1.02 per diluted share, up from $0.62 a year earlier.Analysts polled by FactSet expected $0.87.Revenue in the three months ended June 30 rose to $6.62 billion from $6.05 billion a year earlier.Analysts projected $6.47 billion.Block expects Q3 adjusted diluted EPS of $1.02. Analysts project $1.01.The company increased full-year adjusted EPS guidance to $4.02 from the prior outlook of $3.85. Analysts project $3.90.Block shares fell 1.7% in after-hours trading.